# Neomorph

Source: https://onco.cc/companies/neomorph/  
OnCo record `neomorph` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Neomorph makes small molecules called molecular glues that stick a disease protein to the cell's disposal machinery so it is destroyed. Its first drug is in an early trial for clear cell kidney cancer.

## Summary

Neomorph is a San Diego company that engineers neomorphic protein surfaces to discover molecular glue degraders, claiming the largest proprietary molecular glue target space with multiple newly identified degrons, glue libraries and a broad portfolio of E3 ubiquitin ligases. Its lead programme, NEO-811, degrades ARNT (HIF-1 beta) and is in a first-in-human phase 1/2 monotherapy trial in advanced clear cell renal cell carcinoma; two undisclosed solid tumour programmes and early oncology, immunology, neurology and cardiometabolic targets follow. Partnerships include an option-to-license deal with AbbVie in oncology and immunology (January 2025, up to 1.64 billion US dollars), a multi-target collaboration with Biogen, and work with Novo Nordisk. Neomorph closed a 100 million US dollar Series B in April 2026 led by Deerfield Management.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: San Diego, CA
- Type: biotech
- Website: https://neomorph.com/

## Notes

- Series A and founding year not sourced; no SEC Form D filings were found under the company name. NEO-811's target (ARNT/HIF-1 beta) has no id in the target list.

## Sources

- Official website: https://neomorph.com/
- Pipeline: https://neomorph.com/pipeline/
- Series B press release: https://neomorph.com/press-release/neomorph-announces-closing-of-100-million-series-b-financing/
- AbbVie collaboration: https://neomorph.com/press-release/abbvie-and-neomorph-announce-collaboration-to-develop-molecularglue-degraders-for-oncology-and-immunology/

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- companies: [Alexandria Venture Investments](https://onco.cc/companies/alexandria-venture-investments/), [Deerfield Management](https://onco.cc/companies/deerfield-management/), [Longwood Fund](https://onco.cc/companies/longwood-fund/)

---
JSON: https://onco.cc/api/v1/entities/neomorph.json